Chronic myeloid leukemia is a myeloproliferative neoplasm that can typically be effectively treated with TKIs, improving survival similar to that of a general age-matched population. Many patients require continuous TKI therapy. Therefore, TKI therapy should be selected with consideration of adverse effects, and patients should be helped to maximize adherence to TKI treatment.
No takes yet. Share an insight, caveat, or question.
Jabbour et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: